论文部分内容阅读
目的探讨多药耐药（ＭＤＲ１）基因表达与原发性上皮性卵巢癌（ＰＥＯＣ）耐药的关系及其临床意义。方法应用半定量逆转录—聚合酶链反应（ＲＴ－ＰＣＲ）技术，对３７例ＰＥＯＣ、１０例正常卵巢上皮组织和２０例正常女性外周血单核细胞（ＰＢＭＣ）新鲜标本ＭＤＲ１基因表达进行了检测；并用四氮唑蓝（ＭＴＴ）法，检测了这３７例ＰＥＯＣ患者的原代癌细胞对临床常用抗癌药物的敏感性。结果ＰＥＯＣ标本中ＭＤＲ１基因阳性表达率为３０％，而正常卵巢上皮组织和ＰＢＭＣ则无ＭＤＲ１基因表达；ＭＤＲ１基因表达与ＰＥＯＣ临床期别及组织学类型无关，而与组织学级别有关，且有随级别升高而升高的趋势；ＭＤＲ１基因阳性表达组与阴性组比较，ＤＡＣＴ、ＡＤＭ、Ｅ－ＡＤＭ、ＶＣＲ和ＶＰ１６对ＰＥＯＣ细胞抑制率差异有显著性，其余则无显著性；ＭＤＲ１基因表达与无进展生存期有关，而与总体生存期无关。结论ＭＤＲ１基因表达与ＰＥＯＣ耐药有关，是抗ＭＤＲ相关药物的主要原因；ＭＤＲ１基因表达的检测，对临床用药有指导意义，对临床疗效判断和患者预后预测有一定价值。
Objective To investigate the relationship between multidrug resistance (MDR1) gene expression and drug resistance in primary epithelial ovarian cancer (PEOC) and its clinical significance. Methods The expression of MDR1 gene in fresh specimens of 37 cases of PEOC, 10 cases of normal ovarian epithelial tissue and 20 cases of normal female peripheral blood mononuclear cells (PBMC) was detected by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) . The sensitivity of primary cancer cells in 37 PEOC patients to commonly used anti-cancer drugs was detected by MTT assay. Results The positive rate of MDR1 gene in PEOC specimens was 30%, while the normal ovarian epithelial tissues and PBMCs had no MDR1 gene expression. The expression of MDR1 gene was not related to the clinical stage and histological type of PEOC, but was related to histological grade (P <0.05) .Compared with the negative group, the inhibition rates of DACT, ADM, E-ADM, VCR and VP16 on PEOC were significantly different, while the others were not significant. The expression of MDR1 gene was correlated with Progress-free survival has nothing to do with overall survival. Conclusions MDR1 gene expression is associated with PEOC resistance and is the main cause of anti-MDR related drugs. The detection of MDR1 gene expression is of guiding significance to clinical medication, which has certain value in judging clinical curative effect and prognosis of patients.